Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis, ESC Heart Failure, March 4, 2025

A recent study published in ESC Heart Failure (March 4, 2025) compared initial monotherapy versus combination therapy in pulmonary arterial hypertension (PAH) patients with cardiovascular comorbidities. Results showed that the combination therapy group experienced greater improvements in functional class, BNP/NT-proBNP levels, and overall risk status compared to monotherapy patients. However, no significant differences were observed […]

Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis, ESC Heart Failure, March 4, 2025 Read Post »

“Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox”, International Journal of Cardiology Congenital Heart Disease (Volume 9, March 2025)

A recent analysis published in the International Journal of Cardiology Congenital Heart Disease (Volume 9, March 2025) examines the evolving landscape of pulmonary arterial hypertension (PAH). While traditionally viewed as primarily affecting young adult women without other health conditions, newer registry data from developed countries reveals a shift toward older patients with multiple co-morbidities like

“Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox”, International Journal of Cardiology Congenital Heart Disease (Volume 9, March 2025) Read Post »

Revisiting treatment of pulmonary arterial hypertension in the current era: A Greek scientific document, Hellenic Journal of Cardiology, February 19, 2025

The authors of the study “Revisiting treatment of pulmonary arterial hypertension in the current era: A Greek scientific document” published in the Hellenic Journal of Cardiology on February 19, 2025, presents a country-specific approach to care developed by a multidisciplinary team of cardiologists, pulmonologists, and intensivists. The authors discuss the advances in the field of

Revisiting treatment of pulmonary arterial hypertension in the current era: A Greek scientific document, Hellenic Journal of Cardiology, February 19, 2025 Read Post »

Miniature three dimensional arterial structures may allow proxy evaluation of human pulmonary artery contractility, British Journal of Pharmacology, February 20, 2025

The authors of a study titled “Engineered pulmonary artery tissues for measuring contractility, drug testing and disease modelling”, published in the British Journal of Pharmacology on Ferbruary 20, 2025, present an innovative technique to allow proxy evaluation of human pulmonary artery contractility. Vasoreactivity of the pulmonary arteries regulates blood flow through the lungs,they say, and

Miniature three dimensional arterial structures may allow proxy evaluation of human pulmonary artery contractility, British Journal of Pharmacology, February 20, 2025 Read Post »

Cereno Scientific launches sub-study on drug candidate CS1 for Pulmonary Arterial Hypertension, February 19, 2025

Cereno Scientific has received approval to initiate a sub-study within its Expanded Access Program (EAP) for CS1, a drug candidate aimed at treating pulmonary arterial hypertension. The study will use Functional Respiratory Imaging (FRI) technology, developed by Fluidda, to monitor changes in small pulmonary arteries over a 12-month period. This innovative approach aims to explore

Cereno Scientific launches sub-study on drug candidate CS1 for Pulmonary Arterial Hypertension, February 19, 2025 Read Post »

The latest National Audit of Pulmonary Hypertension in the United Kingdom shows high levels of care despite increasing number of patients

Every year, the National Audit of Pulmonary Hypertension (NAPH) measures the quality of care provided to pulmonary hypertension patients in the United Kingdom by asking specialist centres to provide data that is then compared against a set of 15 agreed standards. The latest audit, covering 2023-24, shows that high levels of care continue – despite centres seeing

The latest National Audit of Pulmonary Hypertension in the United Kingdom shows high levels of care despite increasing number of patients Read Post »

Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients, The Lancet, February 20, 2025

An article titled “Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients”, was published in The Lancet on February 20, 2025. It reports on discussions held between a group of international experts at the 20th Global CardioVascular Clinical Trialists Forum, CVCT (Washington DC, USA), patients’ representatives, and members

Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients, The Lancet, February 20, 2025 Read Post »

Medication Non-Adherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association (PHA) Registry (PHAR), Annals of the American Thoracic Society, February 18, 2025

Medication non-adherence in pulmonary arterial hypertension (PAH) can significantly impact patient outcomes, yet its prevalence and consequences remain understudied. This multi-center registry analysis examined self-reported non-adherence rates among pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (CTEPH) patients, identifying key socioeconomic predictors and associated healthcare outcomes. Using data from the Pulmonary Hypertension Association Registry (PHAR),

Medication Non-Adherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association (PHA) Registry (PHAR), Annals of the American Thoracic Society, February 18, 2025 Read Post »

New data on seralutinib presented at the Pulmonary Vascular Research Institute conference in Rio, January 29-February 1, 2025

Gossamer Bio, Inc. presented clinical and preclinical data related to its investigational drug seralutinib at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress that took place January 29th through February 1st in Rio de Janeiro, Brazil. Of particular interest the data on sustained benefit of seralutinib over nearly 1.5 years, and the evidence, from preclinical

New data on seralutinib presented at the Pulmonary Vascular Research Institute conference in Rio, January 29-February 1, 2025 Read Post »

Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies, European Respiratory Journal, January 30, 2025

This post-hoc, exploratory pooled analysis, published on January 30, 2025, on the European Respiratory Journal, combines data from the Phase 2 PULSAR and Phase 3 STELLAR studies on sotatercept, both international, multicentre, randomised, double-blind, placebo-controlled trials in pulmonary arterial hypertension patients. Out of 429 randomised patients, 237 received sotatercept and 192 placebo. After 24 weeks,

Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies, European Respiratory Journal, January 30, 2025 Read Post »

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis

Merck/MSD announced today that the Phase 3 HYPERION trial on pulmonary arterial hypertension patients (Group 1 World Health Organisation) in functional class II-III was suspended. Patients in the study will be offered the option of receiving WINREVAIR through the Phase 3 SOTERIA open-label extension study. Findings from the HYPERION study will be available later this

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis Read Post »

Alivegen’s ALG-801 given orphan drug designation for the treatment of pulmonary arterial hypertension, Pulmonary Hypertension News, January 8, 2025

ALG-801 is a next-generation ligand trap targeting type IIA/IIB activin receptors that selectively sequesters a specific set of molecules that activate the Smad2/3 pathway, known to be involved in pulmonary arterial hypertension. Smad2/3 is implicated in the growth of pulmonary artery smooth muscle cells, which contributes to blood vessel remodeling, essentially structural alterations, and narrowing

Alivegen’s ALG-801 given orphan drug designation for the treatment of pulmonary arterial hypertension, Pulmonary Hypertension News, January 8, 2025 Read Post »

The Dutch Pulmonary Hypertension Association has contributed financially to the RECOMPENSE Phase 4 study on sotatercept conducted by the Amsterdam University Medical Center

The Dutch Pulmonary Hypertension Association, Stichting Pulmonale Hypertensie, has contributed financially with an amount of € 40.000 the RECOMPENSE – Right VEntricular COMPENsation with SotatercEpt – Phase 4 study conducted by the Amsterdam UMC. This research aims to investigate sotatercept’s effects on right ventricular function. Background Several large international studies have already been conducted in

The Dutch Pulmonary Hypertension Association has contributed financially to the RECOMPENSE Phase 4 study on sotatercept conducted by the Amsterdam University Medical Center Read Post »

From basic scientific research to the development of new drugs for pulmonary arterial hypertension: insights from activin-targeting agents, Breathe, January 21, 2025

This article, authored by Prof. Christophe Guignabert, Director of Research at Inserm – Université Paris-Saclay, France, explores the pathophysiology of pulmonary arterial hypertension, focusing on key mechanisms of disease progression. It notes that in the past three decades, significant advancements in treatment, with 12 new drugs, have improved patients’ quality of life, reduced short-term mortality

From basic scientific research to the development of new drugs for pulmonary arterial hypertension: insights from activin-targeting agents, Breathe, January 21, 2025 Read Post »

Simulation of clinical trials of oral treprostinil in pulmonary arterial hypertension using a virtual population, Nature Briefing Journal, January 15, 2025

The study published recently in the Nature Briefing Journal explores using mathematical modeling to address drug development challenges in pulmonary arterial hypertension. Researchers developed a quantitative systems pharmacology (QSP) model in the context of oral treprostinil clinical studies to predict changes in pulmonary vascular resistance and six-minute walk distance by creating a virtual patient population

Simulation of clinical trials of oral treprostinil in pulmonary arterial hypertension using a virtual population, Nature Briefing Journal, January 15, 2025 Read Post »

Only a minority of US patients receive pulmonary arterial hypertension-specific prescriptions from a pulmonary hypertension center, reveal the findings of a recent study

The authors of this article, published on the American Journal of Respiratory and Critical Care Medicine on January 13, 2025 say that guidelines recommend patients with pulmonary arterial hypertension be referred to pulmonary hypertension centers, but little is known about where care is actually delivered in the United States. Prescription patterns were used to estimate

Only a minority of US patients receive pulmonary arterial hypertension-specific prescriptions from a pulmonary hypertension center, reveal the findings of a recent study Read Post »

UK Pulmonary Hypertension Association Chair Dr Iain Armstrong explains what happens next now that sotatercept has been approved in the UK, YouTube

The new pulmonary arterial hypertension treatment sotatercept was approved for use in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA) at the end of December 2024 – but that doesn’t mean it can now be prescribed. In this short video, the Chair of the UK Pulmonary Hypertension Association Dr Iain Armstrong explains

UK Pulmonary Hypertension Association Chair Dr Iain Armstrong explains what happens next now that sotatercept has been approved in the UK, YouTube Read Post »

Positive scientific advice from the US Food and Drug Administration (FDA) for a Phase 2 clinical trial of tiprelestat in pulmonary arterial hypertension

Tiakis Biotech has received positive scientific advice from the US Food and Drug Administration (FDA) for a planned Phase 2 ATHENA clinical trial of tiprelestat in pulmonary arterial hypertension. The therapy has been granted orphan designation in the U.S. and in Europe for pulmonary arterial hypertension. Dr. Roham Zamanian, Professor of Medicine at Stanford University and

Positive scientific advice from the US Food and Drug Administration (FDA) for a Phase 2 clinical trial of tiprelestat in pulmonary arterial hypertension Read Post »

Challenges in implementing the new European clinical guidelines in Central and Eastern Europe: a review from the Polish Heart Journal 

An article published in the Polish Heart Journal on December 23, 2024, titled “Emerging therapies and new directions in the treatment of pulmonary arterial hypertension” points out that the integration of novel therapeutic protocols into everyday medical practice faces various obstacles, particularly when considering regional differences in implementation. The paper draws insights from medical experts

Challenges in implementing the new European clinical guidelines in Central and Eastern Europe: a review from the Polish Heart Journal  Read Post »

Proud to celebrate the 14 live webinars we have organised since the series launched in June 2023! A huge thank you to all our speakers and participants!

The Alliance for Pulmonary Hypertension (AfPH) recently concluded its 14th webinar, marking the culmination of an educational initiative that began in June 2023. These virtual gatherings brought together internationally renowned experts in pulmonary hypertension, who shared their expertise on a comprehensive range of topics crucial to advancing patient care and quality of life. The diverse

Proud to celebrate the 14 live webinars we have organised since the series launched in June 2023! A huge thank you to all our speakers and participants! Read Post »

TRANSLATE »
Scroll to Top